新型靶向药吉瑞替尼在伴FLT3突变急性髓系白血病治疗的临床应用进展  

Clinical application progress of novel targeted drug gilteritinib in treatment of acute myeloid leukemia with FLT3 mutation

作　　者：张荣莉 姜尔烈 Zhang Rongli;Jiang Erlie(Haihe Laboratory of Cell Ecosystem,National Clinical Research Center for Blood Diseases,State Key Laboratory of Experimental Hematology,Chinese Academy of Medical Sciences&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Institute of Hematology,Tianjin 300020,China)

机构地区：[1]中国医学科学院血液病医院(中国医学科学院血液学研究所)实验血液学国家重点实验室国家血液系统疾病临床医学研究中心、细胞生态海河实验室,天津300020

出　　处：《白血病．淋巴瘤》2023年第6期377-381,共5页Journal of Leukemia & Lymphoma

摘　　要：伴有FLT3突变的急性髓系白血病(AML)患者复发风险高、预后差, 以索拉非尼为代表的一代靶向FLT3的药物在治疗AML中存在选择性差、疗效弱等特征, 以吉瑞替尼为代表的新型的二代FLT3抑制剂对FLT3的抑制作用更强、特异性更高、脱靶毒性更低, 大大提高了伴FLT3突变的AML患者的疗效。文章就吉瑞替尼的作用机制及临床应用进展进行综述。Acute myeloid leukemia(AML)patients with FLT3 mutation have a high risk of recurrence and poor prognosis.The first generation of drugs targeting FLT3 represented by sorafenib show poor selectivity and efficacy in the treatment of AML,whereas the new second-generation FLT3 inhibitors represented by gilteritinib have a stronger inhibitory effect on FLT3,higher specificity and lower off-target toxicity,which greatly improves the outcomes of AML patients with FLT3 mutation.This article reviews the action mechanism and the clinical progress of gilteritinib.

关 键 词：白血病 髓系 急性 基因突变 fms样酪氨酸激酶3 吉瑞替尼 

分 类 号：R733.71[医药卫生—肿瘤]